Trial Profile

A Phase 1, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Combinations of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Subjects With Locally Advanced or Metastatic Solid Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 16 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Budigalimab (Primary) ; Giloralimab (Primary) ; Revdofilimab (Primary) ; Carboplatin; Paclitaxel
Indications Adenocarcinoma; Advanced breast cancer; HER2 positive breast cancer; Non-small cell lung cancer; Solid tumours; Triple negative breast cancer
Focus Adverse reactions; Therapeutic Use
Sponsors AbbVie

12 Aug 2024 Planned End Date changed from 29 Sep 2024 to 30 Mar 2025.
12 Aug 2024 Planned primary completion date changed from 29 Sep 2024 to 30 Mar 2025.
10 May 2024 Planned End Date changed from 12 Nov 2023 to 29 Sep 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com